This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oh, W. K. Articles by Kantoff, P. W. Search for Related Content PubMed PubMed Citation Articles by Oh, W. K. Articles by Kantoff, P. W.

Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?

From the Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Address reprint requests to William K. Oh, MD, 44 Binney St, Boston, MA 02115; email william_oh{at}dfci.harvard.edu

ABSTRACT

PURPOSE: Management of locally advanced prostate cancer remains controversial. Various single and combination modality approaches have been advocated, but an accepted standard of care remains undefined. The purpose of this review is to define the current knowledge in managing locally advanced prostate cancer and to propose new treatment approaches based on current knowledge.

MATERIALS AND METHODS: A MEDLINE search to detect all relevant articles on the management of locally advanced prostate cancer was performed. A review of the staging, natural history, and prognosis of this disease was also performed.

RESULTS: The lack of a clearly defined treatment approach to patients with locally advanced prostate cancer stems from multiple factors, including ambiguities in clinical staging, inadequate knowledge of the natural history of the cancer, and a dearth of comparative randomized trials evaluating efficacy of different therapies. Single modality treatment, including radical prostatectomy (RP) or external-beam radiotherapy alone, is associated with high rates of failure. The use of adjuvant hormonal ablation therapy in combination with external-beam radiotherapy has shown improvement in progression-free and overall survival, although similar improvements have not been clearly demonstrated for surgical patients treated with hormonal therapy. New advances in chemotherapy for hormone-refractory prostate cancer suggest that response rates may be as high as 50% or more, and current trials are evaluating the addition of chemotherapy to hormonal ablation in either surgery or radiation therapy in locally advanced prostate cancer.

CONCLUSION: Optimal management of locally advanced prostate cancer remains undefined. Standard treatment options include RP, external-beam radiotherapy, or hormonal ablation therapy, alone or in combination. New approaches being tested include improved methods for delivering radiation or combining hormonal ablation with surgery or radiation. It is possible that other forms of systemic therapy, including chemotherapy, may become important components of multimodality treatment. Clinical trials designed to test this hypothesis are ongoing.

This article has been cited by other articles:

				N. J. Sanfilippo, S. S. Taneja, A. Chachoua, H. Lepor, and S. C. Formenti Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2973 - 2978. [Abstract] [Full Text] [PDF]

				P. G. Febbo, A. Thorner, M. A. Rubin, M. Loda, P. W. Kantoff, W. K. Oh, T. Golub, and D. George Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer Clin. Cancer Res., January 1, 2006; 12(1): 152 - 158. [Abstract] [Full Text] [PDF]

				P. G. Febbo, J. P. Richie, D. J. George, M. Loda, J. Manola, S. Shankar, A. Szot Barnes, C. Tempany, W. Catalona, P. W. Kantoff, et al. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5233 - 5240. [Abstract] [Full Text] [PDF]

				M. A. Khan and A. W. Partin Management of High-Risk Populations with Locally Advanced Prostate Cancer Oncologist, June 1, 2003; 8(3): 259 - 269. [Abstract] [Full Text] [PDF]

				S. K. Cheema, S. K. Mishra, V. M. Rangnekar, A. M. Tari, R. Kumar, and G. Lopez-Berestein Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter J. Biol. Chem., May 23, 2003; 278(22): 19995 - 20005. [Abstract] [Full Text] [PDF]

				D.-C. Yu, Y. Chen, J. Dilley, Y. Li, M. Embry, H. Zhang, N. Nguyen, P. Amin, J. Oh, and D. R. Henderson Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel Cancer Res., January 1, 2001; 61(2): 517 - 525. [Abstract] [Full Text]

				D. Raghavan Prostate Cancer Management Under Scrutiny: One Man's Meta-Analysis Is Another Man's Poisson J. Clin. Oncol., November 1, 1999; 17(11): 3371 - 3373. [Full Text] [PDF]